Isracann Biosciences Inc.

OTC: ISCNF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 24

v0.1 · 5/100 weight · pillars only

↑ listing tenure, disclosure history · ↓ return on equity, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$3.7M

Employees

—

Market cap

$1.8k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2022

Net income-$3.7M-4.7M CAD2022

Operating income-$1.9M-2.4M CAD2022

Total assets$3.2M4.1M CAD2022

Liabilities$3.0M3.8M CAD2022

Equity$232.2k293.7k CAD2022

Revenue trend

FY2017 – FY2022 · USD

$240.9k

FY17

$922.6k

FY18

FY19

FY20

FY21

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Isracann Biosciences Inc. booked $0 in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Trevena, Inc.——Legacy Technology Holdings, Inc.——ManifestSeven Holdings Corporation——Lowell Farms Inc.——

Key facts

CEOAjay Singh Kaila

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: ISCNF

Employees—

IPO date2017-12-15

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.